Locoregional recurrence risk after neoadjuvant chemotherapy: A pooled analysis of nine prospective neoadjuvant breast cancer trials-Reference-Cited by-同舟云学术

Locoregional recurrence risk after neoadjuvant chemotherapy: A pooled analysis of nine prospective neoadjuvant breast cancer trials

Published:2020-05 Issue: Volume:130 Page:92-101
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Werutsky Gustavo,Untch Michael,Hanusch Claus,Fasching Peter A.,Blohmer Jens-Uwe,Seiler Sabine,Denkert Carsten,Tesch Hans,Jackisch Christian,Gerber Bernd,Schneeweiss Andreas,Link Theresa,Krug David,Huober Jens,Rhiem Kerstin,Kühn Thorsten,Vladimirova Valentina,Nekljudova Valentina^ORCID,Loibl Sibylle

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference41 articles.

1. Response-guided neoadjuvant chemotherapy for breast cancer;von Minckwitz;J Clin Oncol,2013

2. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes;von Minckwitz;J Clin Oncol,2012

3. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial;Gianni;Lancet Oncol,2016

4. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis;Cortazar;Lancet,2014

5. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy;Caudle;Breast Cancer Res,2012

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Locoregional recurrence in studies of primary systemic therapy in early invasive breast cancer;The Breast;2024-10

2. α-Lactalbumin mRNA-LNP Evokes an Anti-Tumor Effect Combined with Surgery in Triple-Negative Breast Cancer;Pharmaceutics;2024-07-14

3. Breast Cancer Patient’s Outcomes after Neoadjuvant Chemotherapy and Surgery at 5 and 10 Years for Stage II–III Disease;Cancers;2024-06-30

4. Clinical impact of semi-annual mammography in patients undergoing breast conserving surgery following neoadjuvant therapy;Surgical Oncology Insight;2024-06

5. Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE);ESMO Open;2024-05